PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Systolic heart failure

Drugs in development · updated 30 October 2026

Systolic heart failure: drugs in development

As of 30 October 2026 there are 7 active clinical trials (recruiting or ongoing, phases I–III) on 7 drugs for systolic heart failure. 4 are experimental, that is not yet approved in the United States.

7Active trials
4Experimental drugs
0Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
JK07II1NCT06369298
SRD-001I–II1NCT04703842
LY3971297I1NCT07547540
Nicotinamide ribosideNicotinamide ribonucleosideEarly I1NCT04528004

Sorted by most advanced phase and number of active trials.

Approved drugs in new trials

Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.

DrugMost advanced phaseActive trialsReference trial
DapagliflozinForxiga, Dapagliflozin PropanediolIII1NCT06434025
TirzepatideZepbound, MounjaroIII1NCT07738276
DigoxinLanoxin®, Lanoxicaps®II1NCT06240403

Sorted by most advanced phase and number of active trials.

All 7 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D054143 “Heart Failure, Systolic”.

ItalianoFrançaisDeutsch